• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc. (Amendment)

    2/14/24 3:02:41 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLUE alert in real time by email
    SC 13G/A 1 sc13ga.htm AMENDMENT NO. 3
    CUSIP NO.
    61225M102
     

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 3)*
     

     
    Monte Rosa Therapeutics, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock
     
     
    (Title of Class of Securities)
     

     
    61225M102
     
     
    (CUSIP Number)
     

     
    December 31, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [ ]
    Rule 13d-1(b)
     
    [x]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     





    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Cormorant Global Healthcare Master Fund, LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)

    PN (Partnership)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Cormorant Private Healthcare Fund II, LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)

    PN (Partnership)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP II, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare Fund III, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP III, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares
     
    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares

    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)


    CUSIP NO.
    61225M102
     

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)          [ ]
     
    (b)          [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5          Sole Voting Power
     
    0 shares
    6          Shared Voting Power
     
    0 shares

    Refer to Item 4 below.
    7          Sole Dispositive Power
     
    0 shares
    8          Shared Dispositive Power
     
    0 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.00%

    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)


    CUSIP NO.
    61225M102
     

    Item 1.
     
     
    (a)
    Name of Issuer

       
    Monte Rosa Therapeutics, Inc.
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    321 Harrison Avenue, Suite 900, Boston, MA 02118

    Item 2.
     
     
    (a)
    Name of Person Filing

       
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Private Healthcare Fund II, LP
    Cormorant Private Healthcare GP II, LLC
    Cormorant Private Healthcare Fund III, LP
    Cormorant Private Healthcare GP III, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       

    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
     
    (c)
    Citizenship
       
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Private Healthcare Fund II, LP - Delaware
    Cormorant Private Healthcare GP II, LLC - Delaware
    Cormorant Private Healthcare Fund III, LP - Delaware
    Cormorant Private Healthcare GP III, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
     
    (d)
    Title of Class of Securities
       

    Common Stock
     
     
    (e)
    CUSIP Number
       
    61225M102


    CUSIP NO.
    61225M102
     

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act
     
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
     
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned***
     
     
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

     
    (b)
    Percent of Class
     
     
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.



    CUSIP NO.
    61225M102
     

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote



       
    (ii)
    shared power to vote or to direct the vote

       
    (iii)
    sole power to dispose or to direct the disposition of

       
    (iv)
    shared power to dispose or to direct the disposition of
       
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.
      
     


    CUSIP NO.
    61225M102
     

    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), Cormorant Private Healthcare Fund II, LP (“Fund II”) and Cormorant Private Healthcare Fund III, LP (“Fund III”), as reported herein. Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP II, LLC and Cormorant Private Healthcare GP III, LLC serve as the general partners of the Master Fund, Fund II and Fund III, respectively. Cormorant Asset Management, LP serves as the investment manager to the Master Fund, Fund II and Fund III. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare GP III, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



    CUSIP NO.
    61225M102
     

    Exhibits
    Exhibit
     
    99.1
    Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 8, 2021.
     

     

    CUSIP NO.
    61225M102
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
     
    February 14, 2024
     


     
    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
     
    By: Cormorant Global Healthcare GP, LLC
     
           its General Partner     
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE FUND II, LP
     
    By: Cormorant Private Healthcare GP II, LLC
     
           its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE GP II, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE FUND III, LP
     
    By: Cormorant Private Healthcare GP III, LLC
     
           its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE GP III, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       


    CUSIP NO.
    61225M102
     

     
    CORMORANT ASSET MANAGEMENT, LP
     
    By: Cormorant Asset Management GP, LLC
     
           its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    /s/ Bihua Chen
     
    Bihua Chen



    Get the next $GLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLUE

    DatePrice TargetRatingAnalyst
    12/19/2024$14.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    2/15/2024$11.00Outperform
    Wedbush
    1/3/2023$18.00Equal Weight → Overweight
    Wells Fargo
    10/13/2022$22.00Buy
    UBS
    8/15/2022$20.00Buy
    Jefferies
    4/28/2022$19.00Neutral
    Credit Suisse
    2/10/2022$19.00Equal-Weight
    Wells Fargo
    10/14/2021$20.00Mkt Perform
    SVB Leerink
    More analyst ratings

    $GLUE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.

      10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      5/8/25 7:14:15 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      5/8/25 7:11:22 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Monte Rosa Therapeutics Inc.

      DEFA14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

      4/25/25 4:02:35 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

      SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      11/14/24 1:22:39 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

      SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      11/12/24 10:32:12 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc.

      SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

      10/30/24 5:10:55 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

      VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clin

      5/8/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

      CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue

      4/28/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

      Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr

      3/20/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

      BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea

      12/13/24 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

      BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of

      7/26/23 7:30:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

      BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon

      3/23/23 7:30:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      3/25/25 6:32:00 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Business & Legal Officer Nickson Philip was granted 36,000 shares (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      1/6/25 4:15:17 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Principal Accounting Officer Dunn Edmund was granted 11,850 shares, increasing direct ownership by 85% to 25,794 units (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      1/6/25 4:15:13 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Monte Rosa Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Monte Rosa Therapeutics from Overweight to Equal Weight and set a new price target of $11.00 from $14.00 previously

      12/19/24 7:39:47 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

      Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00

      2/15/24 6:27:11 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00

      1/3/23 8:03:46 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

      4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

      3/25/25 6:32:00 PM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLUE
    Financials

    Live finance-specific insights

    See more
    • Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

      Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr

      3/20/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

      Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for 

      3/11/25 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

      Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.m. ET today BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including l

      10/17/23 7:00:00 AM ET
      $GLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care